PMEF
ADMA icon

Point72 Middle East FZE’s ADMA Biologics ADMA Stock Holding History

Point72 Middle East FZE’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-97,638
Closed -$350K – 1458
2023
Q3 		$350K Buy
97,638
+45,834
+88% +$176K 0.01% 897
2023
Q2 		$191K Buy
+51,804
New +$192K 0.01% 1073

Other funds holding ADMA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return

Point72 Middle East FZE's ADMA Position: Q4 2023 in Review

Point72 Middle East FZE sold out of ADMA Biologics (ADMA) in Q4 2023, closing a stake of 97,638 shares — an estimated $350K sold.

Point72 Middle East FZE first reported a position in ADMA in Q2 2023 and held it in 2 quarters. The position peaked at $350K in Q3 2023. 184 funds tracked by Wall St. Rank hold ADMA as of Q4 2023.

  • Point72 Middle East FZE reported no remaining ADMA Biologics position as of Q4 2023 after selling out during the quarter.
  • Point72 Middle East FZE sold 97,638 ADMA Biologics shares in Q4 2023, an estimated $350K.
  • Point72 Middle East FZE first reported a position in ADMA Biologics in Q2 2023 and held it in 2 quarters.
  • Point72 Middle East FZE's ADMA Biologics position peaked at $350K in Q3 2023.
  • 184 funds tracked by Wall St. Rank held ADMA Biologics as of Q4 2023.

Based on Point72 Middle East FZE's 13F filing for Q4 2023, filed 14 Feb 2024.